Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Center for Research Resources (NCRR)
Age
10–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically documented, aggressive and/or intermediate grade NHL, B-cell and T-cell.
In relapse after first-line conventional chemotherapy. Primary therapy should include a doxorubicin-based regimen.
Patients must have disease sensitive to induction chemotherapy, radiation therapy, and/or radioimmunotherapy. Successful treatment of CNS or meningeal disease is allowed.
Patients must have accessible tumor for biopsy or excision.
Cumulative total doxorubicin: \<500 mg/m2
Performance score 0-2
No prior pelvic RT
Patients may not be taking immunosuppressive agents.
Informed Consent; IRB approval
Clareo Health | Tumor Lysate Pulsed-Dendritic Cell Vaccines After High-Dose Chemotherapy for Non-Hodgkin's Lymphoma
